SergioA.GiraltMD

Hematologic Oncology

Chief Adult BMT Service Memorial Sloan Kettering Cancer Center

Overview of Dr. Giralt

Dr. Sergio Giralt is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Central University of Venezuela and has been in practice 34 years. Dr. Giralt accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.

Office
1275 York Ave
# 235
New York, NY 10065
Book by Phone+1(785) 246-7364

Fax+1 212-639-3861

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1993
TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986 - 1989
Central University of VenezuelaClass of 1983

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2010 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2021 - 2025
TX State Medical License 1991 - 2025
OH State Medical License 1989 - 1998
American Board of Internal Medicine Internal Medicine

Clinical Trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Start of enrollment: 1995 Aug 01
Completed
Phase 1, Phase 2
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Start of enrollment: 1995 Aug 01
Completed
Phase 1, Phase 2
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Start of enrollment: 1994 Oct 01
Completed
Phase 2
Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Study of Gelonin Purging of Autologous Stem Cells for Transplantation Start of enrollment: 2002 Jul 01
Terminated
Phase 1, Phase 2
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
Completed
Phase 3
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma Start of enrollment: 2004 Jan 01
Completed
Phase 2
Telemedicine Evaluation for Stem Cell Transplant Patients Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant Start of enrollment: 2011 Aug 01
Completed
Not Applicable
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance Start of enrollment: 2011 Oct 28
Completed
Phase 2
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation Start of enrollment: 2012 May 05
Completed
Phase 2
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 Dec 01
Active, not recruiting
Phase 2
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 May 28
Completed
Phase 1, Phase 2
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2017 Aug 28
Completed
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
The Ambient Light Multiple Myeloma Study Start of enrollment: 2023 Feb 13
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

256 citations
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan, Laura W. Dillon, Gege Gui, Brent R. Logan, Mingwei Fei
Journal of Clinical Oncology. 2020-04-20
437 citations
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine
Journal of Clinical Oncology. 2017-02-13
1345 citations
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Mye...
Joan Bladé, Diana Samson, Donna E. Reece, Jane F. Apperley, Bo Björkstrand
British Journal of Haematology. 1998-09-01

Journal Articles

Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma
Parastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature
End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center
Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Lo...
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) ...
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation
Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse
60th American Society of Hematology Annual Meeting - 12/1/2018
Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical OncologySeptember 20th, 2024
Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL WebinarFebruary 27th, 2023
$Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia$
Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid LeukemiaFebruary 18th, 2023
Join now to see all

Other Languages

Spanish

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
GHI PPO
Great West PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Regence Oregon - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment